June 2019

Twitter logo for website footers 2

 

2018 Speakers

Expand/Collapse

Ronald Leathers
Senior Manager Strategic Alliances, Stem Cell Sciences, Cell Therapy & Cell Biology Life Sciences Solutions
Thermo Fisher Scientific

Day Two

Thursday 28th June, 2018

10.30 | A Novel Suspension-based Lentiviral Production Platform to Achieve Cost-Effective Clinical Manufacturing

Justin Coombs
Managing Director & CEO
Carina Biotech

Day Two

Thursday 28th June, 2018

10.00 | Development of a Broad-spectrum Solid Cancer CAR-T Cell

Lietao Li
Founder & CEO
Lion TCR

Day Two

Thursday 28th June, 2018

14.35 | TITLE TBC

Cameron MacKenzie
Director, Business Development
TC Biopharm

Day Two

Thursday 28th June, 2018

15.35 | What Can Gamma Delta T Cells Contribute to the Future of CAR-T?

Zhang Yu
President & CEO
Aeon Therapeutics

Day One

Wednesday 27th June, 2018

14.30 | Developing TCR-mimic CAR-T to Treat Patients with Solid Tumors in China

Zonghai Li
CEO
CARsgen Therapeutics

Day One

Wednesday 27th June, 2018

12.30 | Development of CAR-T Against Solid Tumors

Tony Liu
CEO
Cellular Biomedicine Group

Day Two

Thursday 28th June, 2018

12.35 | Digital Manufacturing of CAR-T cells

Mark Sawicki
CCO
Cryoport

Day Two

Thursday 28th June, 2018

15.05 | Cryo Chain Strategies: From Research to Commercialization

Philip Vanek
GM, Cell Therapy Growth Strategy
GE Healthcare

Day Two

Thursday 28th June, 2018

14.05 | Smart, Closed & Connected Solutions for Cell Therapy Production

Patrick Hanley
Laboratory Facility Director, Cellular Therapy Stem & Cell Processing, Assistant Professor of Pediatrics, Children's National Health System
The George Washington University

Day One

Wednesday 27th June, 2018

16.30 | Overcoming Challenges in the Cellular Therapy Laboratory

Ting He
CEO
ImmunoChina Pharmaceuticals

Day Two

Thursday 28th June, 2018

09.30 | Development of CAR-T Therapy for Hematological Malignancies

Lei Xiao
CEO
Innovative Cellular Therapeutics

Day One

Wednesday 27th June, 2018

13.00 | Moving Forward to Treat Solid Tumor by CAR-T Cell

Sicco Popma
CEO
IO Biosciences

Ian Johnston
Industrial & Academic Cooperations Manager, Senior Project Manager
Miltenyi Biotec

Day Two

Thursday 28th June, 2018

12.05 | Simplifying CAR T Cell Manufacture Through the Use of a Single, Closed System Device

Frank Fan
CSO
Nanjing Legend Biotechnology

Day One

Wednesday 27th June, 2018

10.00 | Clinical Update on Anti-BCMA CAR-T: LCAR-B38M

10.30 | Question Time: Leader Q&A

Pascal Touchon
Senior Vice President, Global Head Cell & Gene
Novartis Oncology

Day One

Wednesday 27th June, 2018

10.30 | Question Time: Leader Q&A

09.30 | Kymriah: The Journey of the First Approved CAR-T from Bench to Ensuring Global Availability for Patients

Jim Freeth
Co-managing Director
Retrogenix

Day One

Wednesday 27th June, 2018

15.00 | Screening CAR T Cells for Target Specificity Using Human Cell Microarray Technology

John Connolly
CSO
Tessa Therapeutics

Peter Sun
CEO
TIMMUNE